Stocks to Track: Windtree Therapeutics, Inc. (NASDAQ: WINT) Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference
On Wednesday, Shares of Windtree Therapeutics, Inc. (NASDAQ: WINT) rose 2.01% to $1.02. The stock recorded $0.9700 as its minimum price and hit the max level of $1.4300, during its …
Stocks to Track: Windtree Therapeutics, Inc. (NASDAQ: WINT) Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference Read More